Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular

First-Half 2026 and Recent Highlights:Raised $10 million through the Company's equity line facil

Interim CEO Efraim Cohen-Arazi Details $10 Million in New Capital, LayerBio's Preparations for the P

TEL AVIV, Israel, July 21, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or t

Battery-to-Revenue Intelligence is a new capability designed to extend the platform’s optimization w

New Capability Builds on Recently Completed Real-World Validation of DeepSolar Predict™ as the Solut

The validation applied real-world historical weather data, renewable energy production records and m

Validation Applied Utility-Scale Renewable Production, Weather and Market Data Across Day-Ahead and

PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF" or the "Company"), a clinical-stage spec

Additional data reported by an independent research firm show comparable analgesic efficacy to ZYNRE

On June 18, 2026, PRF Technologies Ltd. (the "Company") entered into a Standby Equity Purcha

HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open

PRF Technologies (NASDAQ: PRFX) stock falls sharply Monday morning. Read why analysts see this as a

PRF Technologies (NASDAQ:PRFX) stock falls sharply Monday morning. Read why analysts see this as a m

Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce

Dell beats massive estimates, IBM launches $5B Project Lightwell, CrowdStrike expands cyber insuranc

Dell Technologies Inc. (DELL) stock rises 38.7% in premarket trading after strong fiscal Q1 sales an

PRF Technologies Ltd. shares surged 186.22% in after-hours trading after advancing its AI-driven ene

Platform builds on NVIDIA Connect participation and previously announced weather-domain patent filin

PRF-110 is a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine desi

Ropivacaine-only, NSAID-free formulation leverages a long-acting local anesthetic with a favorable s

Milestone supports advancement of PRF's drop-less ocular drug-delivery platform into next-stage U.S.

PRF Technologies gains FDA IND clearance for OcuRing-K, advancing Phase 2 trial plans for drop-less

PRF Technologies outlines 2025 progress, with OcuRing-K ocular drug-delivery advancement and AI sola

PainReform Ltd. (NASDAQ: PRFX - Get Free Report) was the target of a large decrease in short interes

LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth

LayerBio's OcuRing™-K program and broader ocular platform strengthen PRF's healthcare growth strateg

PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today announced a comme

TEL AVIV, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or

Agreement Initiates Data-Driven Technical Due Diligence of an Operational, Utility-Scale Solar Asset

PRF Technologies (Nasdaq: PRFX) ("PRF" or the "Company"), through its DeepSolar™ AI-

TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (Nasdaq: PRFX) (“PRF” or the “C

Patent filing follows acceptance into the NVIDIA Connect Program Proprietary software targets weathe

Patent filing follows acceptance into the NVIDIA Connect Program  Proprietary software targets weath